Copyright
©The Author(s) 2020.
World J Gastrointest Surg. Apr 27, 2020; 12(4): 149-158
Published online Apr 27, 2020. doi: 10.4240/wjgs.v12.i4.149
Published online Apr 27, 2020. doi: 10.4240/wjgs.v12.i4.149
Figure 1 Survival of patients with mammalian target of rapamycin inhibitor vs no mammalian target of rapamycin inhibitor (survival 21.
0 ± 4.1 vs 11.2 ± 2.5 mo, P = 0.04). mTOR: Mammalian target of rapamycin.
- Citation: Au KP, Chok KSH. Mammalian target of rapamycin inhibitors after post-transplant hepatocellular carcinoma recurrence: Is it too late? World J Gastrointest Surg 2020; 12(4): 149-158
- URL: https://www.wjgnet.com/1948-9366/full/v12/i4/149.htm
- DOI: https://dx.doi.org/10.4240/wjgs.v12.i4.149